Given our increasingly aging society, the number of patients with malignant urogenital diseases (e.g., prostate cancer, urothelial cancer, renal cell carcinoma) is increasing. Meanwhile, overdiagnosis and overtreatment are also problems, especially given the morbidities of many of the treatments available such as radical prostatectomy or radical cystectomy.

Disclosure:
The series “Urinary Biomarkers of Urothelial Malignancies” was commissioned by the editorial office, Translational Andrology and Urology without any sponsorship or funding. Kazutoshi Fujita is serving as the unpaid Guest Editor for the series.